Craig Hallum Issues Pessimistic Forecast for MaxCyte (NASDAQ:MXCT) Stock Price

MaxCyte (NASDAQ:MXCT) had its target price lowered by stock analysts at Craig Hallum from $7.00 to $5.00 in a research report issued on Wednesday,Benzinga reports. The brokerage presently has a “buy” rating on the stock.

Other analysts have also recently issued research reports about the stock. Wall Street Zen cut shares of MaxCyte from a “hold” rating to a “sell” rating in a research report on Monday. Weiss Ratings reissued a “sell (e+)” rating on shares of MaxCyte in a research note on Monday, December 29th. Two analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, MaxCyte presently has a consensus rating of “Hold” and an average target price of $5.50.

MaxCyte Stock Down 3.6%

NASDAQ MXCT traded down $0.03 during trading on Wednesday, reaching $0.71. 766,681 shares of the stock traded hands, compared to its average volume of 1,114,390. The firm has a market cap of $76.06 million, a price-to-earnings ratio of -1.62 and a beta of 1.22. The stock’s 50-day moving average price is $0.88 and its 200 day moving average price is $1.33. MaxCyte has a fifty-two week low of $0.64 and a fifty-two week high of $3.10.

MaxCyte (NASDAQ:MXCT) last posted its earnings results on Tuesday, March 24th. The company reported ($0.06) earnings per share for the quarter, topping the consensus estimate of ($0.08) by $0.02. The company had revenue of $6.76 million for the quarter, compared to analyst estimates of $9.16 million. MaxCyte had a negative net margin of 132.57% and a negative return on equity of 23.50%. Analysts anticipate that MaxCyte will post -0.42 EPS for the current fiscal year.

Institutional Investors Weigh In On MaxCyte

Institutional investors have recently added to or reduced their stakes in the stock. Mirabella Financial Services LLP increased its holdings in MaxCyte by 24.2% during the 3rd quarter. Mirabella Financial Services LLP now owns 8,200,000 shares of the company’s stock worth $12,956,000 after purchasing an additional 1,600,000 shares in the last quarter. State Street Corp lifted its holdings in shares of MaxCyte by 4.0% in the fourth quarter. State Street Corp now owns 2,358,384 shares of the company’s stock valued at $3,655,000 after purchasing an additional 91,534 shares in the last quarter. AXA S.A. lifted its holdings in shares of MaxCyte by 123.2% in the second quarter. AXA S.A. now owns 2,202,378 shares of the company’s stock valued at $4,801,000 after purchasing an additional 1,215,481 shares in the last quarter. Kennedy Capital Management LLC acquired a new position in shares of MaxCyte during the third quarter worth about $3,330,000. Finally, Millennium Management LLC boosted its position in shares of MaxCyte by 1,082.6% during the fourth quarter. Millennium Management LLC now owns 1,292,773 shares of the company’s stock worth $2,004,000 after buying an additional 1,183,461 shares during the period. 68.81% of the stock is owned by institutional investors.

Trending Headlines about MaxCyte

Here are the key news stories impacting MaxCyte this week:

• Positive Sentiment: Healthy cash runway — MaxCyte reported $155.6M in cash, cash equivalents and investments at year‑end 2025 and said it expects to finish 2026 with at least ~$136M, which should fund operations and strategic initiatives. GlobeNewswire Release
• Positive Sentiment: 2025 revenue at the top of prior prelim range — Full‑year 2025 revenue came in at $33.0M, at the top of MaxCyte’s earlier preliminary range, showing execution on prior guidance. GlobeNewswire Release
• Neutral Sentiment: Earnings call and transcripts available — Management reviewed results and strategy on the Q4 2025 call; full transcripts are posted for investors to evaluate commentary on commercialization progress and program timing. Seeking Alpha Transcript
• Neutral Sentiment: Short‑interest data shown in aggregators appears inconsistent/zero and should be treated as unreliable until exchanges confirm actual figures. (Multiple summary entries flagged anomalous short‑interest values.)
• Negative Sentiment: Q4 missed consensus — MaxCyte reported EPS of $(0.09) vs. consensus ~(0.08) and Q4 revenue of ~$6.75–7.3M, well below analyst expectations of ~$9.16M; net margin and ROE remain deeply negative. MarketBeat Earnings Summary
• Negative Sentiment: 2026 guidance implies a modest revenue decline — Management guided 2026 revenue of $30–32M (Core $25–27M; SPL program ~$5M), below 2025’s $33M, which may signal slower near‑term growth and is likely weighing on sentiment. GlobeNewswire Release

MaxCyte Company Profile

MaxCyte, Inc (NASDAQ: MXCT) is a clinical‐stage cell therapy platform company that develops and commercializes proprietary flow electroporation technology for the delivery of macromolecules into living cells. The company’s instruments and consumables are designed to support research, preclinical development and clinical‐scale manufacturing of cell therapies across a variety of modalities, including engineered T cells, natural killer (NK) cells and induced pluripotent stem cell (iPSC) therapies.